Apollo has created a library of over 60
recombinant human proteins that closely mimic proteins in the human body
because they are expressed from human cells.
Proteins are the basic building blocks of life, controlling diverse
cellular and physiological processes such as metabolism (energy
expenditure), the immune response (involved in fighting diseases) and
memory and learning in the human brain. Apollo’s continually expanding
range of proteins includes cytokines, chemokines, growth factors,
hormones and their receptors.
Apollo’s technology creates proteins that are uniquely human in
composition and attachments. The human-ness of the attachments in
particular is central to how a protein performs its role in the body.
More...
Apollo began developing human-expressed proteins for use as
therapeutics in 2002, responding to the growing demand for more
effective treatments for chronic diseases and age-related disorders, and
growing research interest in the role that protein sugar structures play
in therapeutic outcomes. Apollo built on its experience working with
human cells to produce natural human proteins.
To create the protein library Apollo had to overcome the technical
difficulties of obtaining purified human protein with intact human
attachments at acceptable yields. Apollo has invested significant time
and resources in developing its proprietary knowledge and core
capabilities in the areas of cloning, expression, purification,
quantification and characterization of human cell expressed (hcx™)
recombinant human proteins. We also conduct scientific and preclinical
research to clarify the proteins’ structure and biological function.
This accumulated knowledge provides a platform to devise discovery
and development strategies for new targets, and effectively move them
through the production and analysis stages. The development cycle for
new proteins has been significantly reduced and is continually
streamlined. Apollo’s project teams combine the skills of molecular
biologists, protein chemists, cell biologists, immunologists and
glycoprotein chemists to develop, produce and analyse hcx™ proteins.
Apollo uses the proteins to develop its own next-generation
therapeutics,
and offers research grade proteins for sale. The 60+ lyophilised
proteins currently available as products are >97% pure and undergo stringent quality control and
endotoxin plus stability testing. These uniquely human proteins are
sold to researchers through Apollo Cytokine Research.
A further 60 proteins are at different stages of development.
Top |